Laura Sanz

Dr. Laura Sanz

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
IGIrene Guijarro-Muñoz
Irene Guijarro-Muñoz
MCMarta Compte
Marta Compte
AÁAna Álvarez-Cienfuegos
Ana Álvarez-Cienfuegos
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
LSLaura Sanz
Laura Sanz
Pericytes and mesenchymal stem cells (MSCs) are ontogenically related, and in fact, no significant phenotypic differences could be observed by flow cytometry. Transcriptome analysis of human pericytes and MSCs revealed that 43 genes were up-regulated more than 10-fold in pericytes compared with MSCs. Identification of Toll-like receptor 4 (TLR4) as one of the most abundant RNA species in pericytes with respect to MSCs and confirmation of TLR4 expression on the cell surface led us to obtain a comprehensive overview of the expression program of lipopolysaccharide (LPS)-stimulated pericytes. Transcriptional profiling of LPS-treated cells revealed that 22 genes were up-regulated more than 5-fold. Of them, 10 genes encoded chemokines and cytokines (CXCL10, CCL20, IL8, CXCL1, IL6, CCL2, IL1B, CXCL2, IL1A, and CXCL6), and three genes encoded adhesion molecules (ICAM1, VCAM1, and SELE). LPS induced nuclear translocation of the transcription factor NF-κB in stimulated pericytes. Moreover, inhibition of NF-κB activation by SC-514 blocked LPS-induced up-regulation of a subset of chemokine genes, confirming the key role of NF-κB in LPS signaling in pericytes. At the protein level, we assessed the secretion of the proinflammatory cytokines and chemokines IL-6, IL-8, CXCL1, CXCL2, CXCL3, and CCL2 not only after LPS treatment but also in HMGB1-stimulated pericytes. Up-regulation of the adhesion molecules ICAM-1 and VCAM-1 resulted in an increased adhesion of peripheral blood leukocytes to an LPS-treated pericyte monolayer. The role of pericytes in the inflammatory context has been scarcely addressed; according to these results, pericytes should be considered as active players in the inflammatory cascade with potential physiopathological implications.

4 November 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
RNRocío Navarro
Rocío Navarro
MCMarta Compte
Marta Compte
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
LSLaura Sanz
Laura Sanz
Pericytes are mural cells that surround endothelial cells in small blood vessels. Pericytes have traditionally been credited with structural functions, being essential for vessel maturation and stabilization. However, an accumulating body of evidence suggests that pericytes also display immune properties. They can respond to a series of proinflammatory stimuli and are able to sense different types of danger due to their expression of functional pattern recognition receptors, contributing to the onset of innate immune responses. In this context, pericytes not only secrete a variety of chemokines, but they also overexpress adhesion molecules such as ICAM-1 and VCAM-1 involved in the control of immune cell trafficking across vessel walls. In addition to their role in innate immunity, pericytes are involved in adaptive immunity. It has been reported that interaction with pericytes anergizes T cells, which is attributed, at least in part, to the expression of PD-L1. As components of the tumor microenvironment, pericytes can also modulate the antitumor immune response. However, their role is complex and further studies will be required to better understand the crosstalk of pericytes with immune cells in order to consider them as potential therapeutic targets. In any case, pericytes will be looked at with new eyes by immunologists from now on.

27 July 2023 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
ATAntonio Tapia-Galisteo
Antonio Tapia-Galisteo
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
LSLaura Sanz
Laura Sanz
Immune cell engagers are engineered antibodies with at least one arm binding a tumor-associated antigen and at least another one directed against an activating receptor in immune effector cells: CD3 for recruitment of T cells and CD16a for NK cells. The first T cell engager (the anti-CD19 blinatumomab) was approved by the FDA in 2014, but no other one hit the market until 2022. Now the field is gaining momentum, with three approvals in 2022 and 2023 (as of May): the anti-CD20 × anti-CD3 mosunetuzumab and epcoritamab and the anti-B cell maturation antigen (BCMA) × anti-CD3 teclistamab, and another three molecules in regulatory review. T cell engagers will likely revolutionize the treatment of hematological malignancies in the short term, as they are considerably more potent than conventional monoclonal antibodies recognizing the same tumor antigens. The field is thriving, with a plethora of different formats and targets, and around 100 bispecific T cell engagers more are already in clinical trials. Bispecific NK cell engagers are also in early-stage clinical studies and may offer similar efficacy with milder side effects. Trispecific antibodies (engaging either T cell or NK cell receptors) raise the game even further with a third binding moiety, which allows either the targeting of an additional tumor-associated antigen to increase specificity and avoid immune escape or the targeting of additional costimulatory receptors on the immune cell to improve its effector functions. Altogether, these engineered molecules may change the paradigm of treatment for relapsed or refractory hematological malignancies.

15 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMarta Compte
Marta Compte
SHSeandean Lykke Harwood
Seandean Lykke Harwood
IMInes G. Muñoz
Ines G. Muñoz
RNRocio Navarro
Rocio Navarro
MZManuela Zonca
Manuela Zonca
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
The costimulation of immune cells using first-generation anti-4-1BB monoclonal antibodies (mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development, however, is restricted by significant off-tumor toxicities associated with FcγR interactions. Here, we have designed an Fc-free tumor-targeted 4-1BB-agonistic trimerbody, 1D8N/CEGa1, consisting of three anti-4-1BB single-chain variable fragments and three anti-EGFR single-domain antibodies positioned in an extended hexagonal conformation around the collagen XVIII homotrimerization domain. The1D8N/CEGa1 trimerbody demonstrated high-avidity binding to 4-1BB and EGFR and a potent in vitro costimulatory capacity in the presence of EGFR. The trimerbody rapidly accumulates in EGFR-positive tumors and exhibits anti-tumor activity similar to IgG-based 4-1BB-agonistic mAbs. Importantly, treatment with 1D8N/CEGa1 does not induce systemic inflammatory cytokine production or hepatotoxicity associated with IgG-based 4-1BB agonists. These results implicate FcγR interactions in the 4-1BB-agonist-associated immune abnormalities, and promote the use of the non-canonical antibody presented in this work for safe and effective costimulatory strategies in cancer immunotherapy.

1 May 2015 in Drug Discovery Today
Verified
Journal Article
Closed access
NNNatalia Nuñez-Prado
Natalia Nuñez-Prado
MCMarta Compte
Marta Compte
SHSeandean Harwood
Seandean Harwood
AÁAna Álvarez-Méndez
Ana Álvarez-Méndez
SLSimon Lykkemark
Simon Lykkemark
LALuis Alvarez-Vallina
Luis Alvarez-Vallina

1 January 2023 in Theranostics
Verified
Journal Article
Open access
PDF file
ATAntonio Tapia-Galisteo
Antonio Tapia-Galisteo
MCMarta Compte
Marta Compte
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
LSLaura Sanz
Laura Sanz
Despite the clinical success of the first bispecific antibody approved by the FDA against B cell malignancies (blinatumomab), many obstacles remain such as dosing, treatment resistance, and modest efficacy in solid tumors. To overcome these limitations, considerable efforts have been dedicated to the development of multispecific antibodies, opening up new avenues to address both the complex biology of cancer and the onset of anti-tumoral immune responses. Simultaneous targeting of two tumor-associated antigens is presumed to enhance cancer cell selectivity and reduce immune escape. Co-engagement of CD3, along with agonists of co-stimulatory molecules or antagonists of co-inhibitory immune checkpoint receptors in a single molecule, may revert T cell exhaustion. Similarly, targeting of two activating receptors in NK cells may improve their cytotoxic potency. And these are only examples of the potential of antibody-based molecular entities engaging three (or more) relevant targets. From the perspective of health care costs, multispecific antibodies are appealing, since a similar (or superior) therapeutic effect could be obtained with a single therapeutic agent as with a combination of different monoclonal antibodies. Despite challenges in production, multispecific antibodies are endowed with unprecedented properties, which may render them more potent biologics for cancer therapy.